R P Baum

Summary

Country: Germany

Publications

  1. doi request reprint FDG-PET/CT in lung cancer: an update
    Richard P Baum
    Department of Nuclear Medicine Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany
    Front Radiat Ther Oncol 42:15-45. 2010
  2. ncbi request reprint Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET)
    R P Baum
    Zentralklinik Bad Berka Clinic of Nuclear Medicine, Center for PET, Bad Berka, Germany
    Q J Nucl Med 45:257-68. 2001
  3. ncbi request reprint Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer
    R P Baum
    Department of Nuclear Medicine, Center for PET, Bad Berka, Germany
    Q J Nucl Med Mol Imaging 48:119-42. 2004
  4. doi request reprint Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT
    Vikas Prasad
    Department of Nuclear Medicine and Centre for PET CT, Zentralklinik Bad Berka, Robert Koch Allee 9, 99437 Bad Berka, Germany
    Eur J Nucl Med Mol Imaging 37:67-77. 2010
  5. ncbi request reprint Pancreatic neuroendocrine neoplasms
    D Hörsch
    Center for Neuroendocrine Tumors Bad Berka ENETS, Bad Berka, Germany
    Minerva Gastroenterol Dietol 58:401-26. 2012
  6. doi request reprint The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm
    D Kaemmerer
    Department of General and Visceral Surgery, Zentralklinik Bad Berka, Robert Koch Allee 9, 99437, Bad Berka, Germany
    Clin Exp Metastasis 31:817-27. 2014
  7. doi request reprint [The relevance of PET/CT for the surgical management of neuroendocrine neoplasms]
    M Hommann
    Klinik für Allgemeine Chirurgie Viszeralchirurgie, ENETS Center of Excellence Zentralklinik Bad Berka, Robert Koch Allee 9, 99438, Bad Berka, Deutschland
    Chirurg 85:500-4. 2014
  8. ncbi request reprint Therapeutic nuclear medicine in pediatric malignancy
    M Schmidt
    Department of Nuclear Medicine, University of Cologne, Cologne, Germany
    Q J Nucl Med Mol Imaging 54:411-28. 2010
  9. ncbi request reprint Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides
    D Hörsch
    Zentralklinik Bad Berka, Bad Berka, Germany
    J Clin Oncol 26:4517. 2008
  10. ncbi request reprint Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions
    V Prasad
    Department of Nuclear Medicine Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany
    Q J Nucl Med Mol Imaging 54:61-7. 2010

Collaborators

Detail Information

Publications17

  1. doi request reprint FDG-PET/CT in lung cancer: an update
    Richard P Baum
    Department of Nuclear Medicine Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany
    Front Radiat Ther Oncol 42:15-45. 2010
    ..The aim of this article is to present a concise summary of the present status of FDG-PET/CT...
  2. ncbi request reprint Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET)
    R P Baum
    Zentralklinik Bad Berka Clinic of Nuclear Medicine, Center for PET, Bad Berka, Germany
    Q J Nucl Med 45:257-68. 2001
    ....
  3. ncbi request reprint Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer
    R P Baum
    Department of Nuclear Medicine, Center for PET, Bad Berka, Germany
    Q J Nucl Med Mol Imaging 48:119-42. 2004
    ..The time has come for FDG-PET to find its place in new guidelines for the workup of lung cancer patients...
  4. doi request reprint Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT
    Vikas Prasad
    Department of Nuclear Medicine and Centre for PET CT, Zentralklinik Bad Berka, Robert Koch Allee 9, 99437 Bad Berka, Germany
    Eur J Nucl Med Mol Imaging 37:67-77. 2010
    ....
  5. ncbi request reprint Pancreatic neuroendocrine neoplasms
    D Hörsch
    Center for Neuroendocrine Tumors Bad Berka ENETS, Bad Berka, Germany
    Minerva Gastroenterol Dietol 58:401-26. 2012
    ..These treatment options have been included in guidelines of several professional societies and weighted for sequential therapy of patients with pancreatic neuroendocrine tumors according to effects and side effects...
  6. doi request reprint The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm
    D Kaemmerer
    Department of General and Visceral Surgery, Zentralklinik Bad Berka, Robert Koch Allee 9, 99437, Bad Berka, Germany
    Clin Exp Metastasis 31:817-27. 2014
    ..Immunohistochemical profiling revealed CD302 as the best marker for ileal and PPWD1 for pancreatic detection...
  7. doi request reprint [The relevance of PET/CT for the surgical management of neuroendocrine neoplasms]
    M Hommann
    Klinik für Allgemeine Chirurgie Viszeralchirurgie, ENETS Center of Excellence Zentralklinik Bad Berka, Robert Koch Allee 9, 99438, Bad Berka, Deutschland
    Chirurg 85:500-4. 2014
    ..Imaging with 18F-fluorodeoxyglucose (18F-FDG PET/CT) is indicated in poorly differentiated neuroendocrine carcinomas. The receptor-dependent imaging of NENs has a decisive impact on further management. ..
  8. ncbi request reprint Therapeutic nuclear medicine in pediatric malignancy
    M Schmidt
    Department of Nuclear Medicine, University of Cologne, Cologne, Germany
    Q J Nucl Med Mol Imaging 54:411-28. 2010
    ..54 per 100000 per year but is the most frequent tumour of endocrine glands in children and adolescents. Management includes radioiodine therapy but there are some distinct differences in comparison to adult thyroid cancer management...
  9. ncbi request reprint Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides
    D Hörsch
    Zentralklinik Bad Berka, Bad Berka, Germany
    J Clin Oncol 26:4517. 2008
    ..Lu-TATE was predominantly used for small metastases or in patients with impaired renal or hematological function...
  10. ncbi request reprint Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions
    V Prasad
    Department of Nuclear Medicine Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany
    Q J Nucl Med Mol Imaging 54:61-7. 2010
    ....
  11. ncbi request reprint Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection
    O Schroder
    Department of Nuclear Medicine, Johann Wolfgang Goethe University, Frankfurt Main, Germany
    Nuklearmedizin 37:279-85. 1998
    ..The differentiation of HCC from liver metastasis or benign disorders by imaging studies based upon morphological aspects may be difficult...
  12. ncbi request reprint Paclitaxel/carboplatin (PC) followed by twice daily chemoradiation (hfRT/PC) versus hfRT/PC followed by PC as induction to surgery in stage III non-small cell lung cancer (NSCLC): A randomized phase III trial of the Lung Cancer Study Group Mitteldeutschla
    R Bonnet
    Zentralklinik Bad Berka, Bad Berka, Germany Friedrich Schiller Universität, Jena, Germany Kreiskrankenhaus Greiz, Greiz, Germany Krankenhaus St Georg, Leipzig, Germany SRH Waldklinikum, Gera, Germany Krankenhaus Martha Maria, Halle, Germany Helios Klinikum, Erfurt, Germany Universitätsklinik Bergmsannsheil, Bochum, Germany
    J Clin Oncol 26:7541. 2008
    ..7541 Background: In multimodal neoadjuvant therapy of stage III NSCLC, the potential impact of the sequencing of the different induction modalities on survival has not been evaluated...
  13. doi request reprint Current treatment options for neuroendocrine tumors
    D Hörsch
    Department of Gastroenterology Endocrinology, Zentralklinik Bad Berka GmbH, Bad Berka, Germany
    Drugs Today (Barc) 47:773-86. 2011
    ..In summary, treatment options for neuroendocrine tumors have expanded considerably in the last years leading to prolonged overall survival...
  14. ncbi request reprint A novel technetium-99m labeled monoclonal antibody (174H.64) for staging head and neck cancer by immuno-SPECT
    R P Baum
    Department of Nuclear Medicine, Johann Wolfgang Goethe-University Medical Center, Frankfurt/Main, Germany
    Acta Oncol 32:747-51. 1993
    ....
  15. ncbi request reprint [Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment]
    M Schmücking
    Klinik für Nuklearmedizin PET Zentrum, Zentralklinik Bad Berka
    Pathologe 26:178-89. 2005
    ....
  16. ncbi request reprint Receptor PET/CT imaging of neuroendocrine tumors
    R P Baum
    Zentralklinik Bad Berka GmbH Nuklearmedizinische Klinik, Germany
    Recent Results Cancer Res 170:225-42. 2008
  17. ncbi request reprint Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
    P Antunes
    Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    Eur J Nucl Med Mol Imaging 34:982-93. 2007
    ..In preclinical studies it has shown a striking superiority over its 111In-labelled congener. The purpose of this study was to evaluate whether third-generation somatostatin-based, radiogallium-labelled peptides show the same superiority...